17
Participants
Start Date
September 6, 2019
Primary Completion Date
September 21, 2021
Study Completion Date
February 14, 2024
Pembrolizumab
200 mg IV dose given on day 1 of a three week cycle
Rituximab
375 mg/m2 IV dose given up to 8 times in the trial
Derriford Hospital, Univeristy Hospitals Plymouth NHS Trust, Plymouth
Torbay and South Devon NHS Foundation Trust, Torquay
Royal Bournemouth Hospital, University Hospitals Dorset NHS Foundation Trust, Bournemouth
St Bartholomew's Hospital, Barts Health NHS Trust, London
UCLH, Univeristy College London Hospitals NHS Foundation Trust, London
The Christie Hospital, The Christie NHS Foundation Trust, Manchester
Churchill Hospital, Oxford Univeristy NHS Foundation Trust, Oxford
Bristol Haematology & Oncology Medical Centre, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol
Norfolk and Norwich University Hospital, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich
Merck Sharp & Dohme LLC
INDUSTRY
University College, London
OTHER